Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA releases Xolair documents

FDA's Pulmonary Advisory Committee on Thursday is likely to focus on the clinical relevance of trials of Xolair omalizumab, as well as the ability of physicians to identify asthma patients who could benefit from the anti-IgE antibody from Genentech (DNA), Tanox (TNOX) and Novartis (NVS;

Read the full 455 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers